Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

Completed · Not applicable

Conditions studied: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder

In brief

This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.

Key facts

Study ID

NCT02566057

Run by

Northwell Health

People needed

36

Starts

2014-07-10

Expected to finish

2017-12-31

Last updated by the study team

2018-01-24

Who can join

Age: 15 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 15-64;
• Diagnostic and Statistical Manual Diploma in Social Medicine diagnosis of schizophrenia (DSM IV), schizoaffective disorder, schizophreniform disorder, psychotic disorder NOS, and bipolar disorder;
• Onset of antipsychotic treatment within the past 3 years;
• Able to provide informed consent. (assent for those under age 18)

You may not qualify if…

• Evidence of serious medical conditions,
• Female patients who are pregnant or breast feeding;
• Patients who are not willing to take medications for treatment;
• Patients who are unable to provide informed consent due to impairment in decision-making ability.

Where it is running

• Zucker Hillside Hospital-North Shore Long Island Jewish Health System — Glen Oaks, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.